CSBR · Insider Trading
Champions Oncology, Inc.
Every open-market purchase and sale reported by CSBR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Joel Ackerman | Director | M | +69,794 | +$111.67K |
| 2026-01-30 | Robert Lawrence Brainin | CEO | A | +700,000 deriv. | — |
| 2026-01-30 | Robert Lawrence Brainin | Director | A | +66,131 deriv. | — |
| 2025-11-07 | Joel Ackerman | Director | A | +21,216 deriv. | — |
| 2025-11-07 | Scott R Tobin | Director | A | +25,460 deriv. | — |
| 2025-11-07 | Philip P. Breitfeld | Director | A | +13,790 deriv. | — |
| 2025-11-07 | Daniel Newman Mendelson | Director | A | +13,790 deriv. | — |
| 2025-11-07 | David Sidransky | Director | A | +21,216 deriv. | — |
| 2025-11-06 | Joel Ackerman | Director | M | +94,405 | +$198.25K |
| 2025-04-02 | Philip P. Breitfeld | Director | J | −4,150 | — |
| 2024-11-18 | David Sidransky | Director | A | +21,880 deriv. | — |
| 2024-11-18 | Joel Ackerman | Director | A | +43,190 deriv. | — |
| 2024-11-18 | Daniel Newman Mendelson | Director | A | +21,590 deriv. | — |
| 2024-11-18 | Scott R Tobin | Director | A | +34,550 deriv. | — |
| 2024-11-18 | Philip P. Breitfeld | Director | A | +18,715 deriv. | — |
| 2024-11-01 | Joel Ackerman | Director | M | +105,137 | +$276.29K |
| 2024-04-01 | Brady Davis | President | A | +210,500 deriv. | — |
| 2024-01-16 | Daniel Newman Mendelson | Director | Buy | +1,000 | +$6.50K |
| 2024-01-12 | Daniel Newman Mendelson | Director | Buy | +2,000 | +$12.54K |
| 2024-01-11 | Daniel Newman Mendelson | Director | Buy | +2,944 | +$18.58K |
| 2024-01-10 | Daniel Newman Mendelson | Director | Buy | +3,000 | +$18.75K |
| 2024-01-09 | Daniel Newman Mendelson | Director | Buy | +1,000 | +$6.15K |
| 2024-01-08 | Daniel Newman Mendelson | Director | Buy | +2,000 | +$12.18K |
| 2024-01-08 | Daniel Newman Mendelson | Director | Buy | +3,000 | +$18.36K |
| 2024-01-05 | Joel Ackerman | Director | M | +114,552 | +$240.56K |
| 2024-01-04 | Daniel Newman Mendelson | Director | Buy | +500 | +$2.92K |
| 2023-12-26 | Daniel Newman Mendelson | Director | Buy | +2,500 | +$12.30K |
| 2023-12-21 | Daniel Newman Mendelson | Director | Buy | +2,100 | +$10.12K |
| 2023-12-20 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$23.75K |
| 2023-11-07 | Philip P. Breitfeld | Director | A | +15,495 deriv. | — |
| 2023-11-07 | Scott R Tobin | Director | A | +28,600 deriv. | — |
| 2023-11-07 | David Sidransky | Director | A | +15,495 deriv. | — |
| 2023-11-07 | Daniel Newman Mendelson | Director | A | +26,220 deriv. | — |
| 2023-11-07 | Joel Ackerman | Director | A | +35,750 deriv. | — |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$31.10K |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | +1,500 | +$8.93K |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | +4,000 | +$24.64K |
| 2023-10-13 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$32.00K |
| 2023-10-11 | Daniel Newman Mendelson | Director | Buy | +1,100 | +$7.05K |
| 2023-10-10 | Daniel Newman Mendelson | Director | Buy | +1,530 | +$9.91K |
| 2023-10-06 | Daniel Newman Mendelson | Director | Buy | +2,000 | +$12.94K |
| 2023-10-04 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$32.00K |
| 2023-10-04 | Daniel Newman Mendelson | Director | Buy | +2,500 | +$15.75K |
| 2023-09-27 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$28.25K |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$27.55K |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | +4,018 | +$22.14K |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | +5,000 | +$26.40K |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | +3,812 | +$20.97K |
| 2023-08-17 | Daniel Newman Mendelson | Director | A | +19,430 deriv. | — |
| 2023-08-17 | Joel Ackerman | Director | A | +26,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joel Ackerman | Director | 1,126,333 | $5.47M |
| David Sidransky | Director | 770,605 | $3.75M |
| Daniel Newman Mendelson | Director | 198,625 | $965.32K |
| Scott R Tobin | Director | 30,000 | $145.80K |
| Philip P. Breitfeld | Director | 5,717 | $27.78K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CSBR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.